Amneal Aims To Be Among Top Five Biosimilars Players In US
As Company Focuses On Launch Of Three Biosimilars This Year
Executive Summary
Amneal’s president and co-CEO, Chirag Patel, has shared the company’s long-term plan of becoming one of the top biosimilars players in the US. The company is set to launch three biosimilars this year, while building its manufacturing capabilities and looking for opportunities and partnerships.
You may also be interested in...
Generics Bulletin Editor’s Picks For Q1 2022
Looking back over the first quarter of 2022, Generics Bulletin executive editor David Wallace picks out highlights from January to March that include a number of major deals in the biosimilars sector, warnings of increasing price pressure on generics, and key strategy updates from companies across the off-patent sector.
Amneal Acquires India’s Puniska To Double Injectables Business
Amneal has acquired India’s Puniska Pharmaceticals in a deal worth $93m, with an aim to “more than double” its injectables business by 2025. Meanwhile, in the third quarter the company has reported growth in its generics and specialty segments, with Amneal looking to enter the biosimilars market next year.
Amneal’s IPX-203 Increases ‘Good’ ON Time For Parkinson’s Patients
The proprietary carbidopa/levodopa formulation increased good ON time with fewer doses versus immediate-release levodopa. A post-hoc analysis also showed 1.55 hours more ON time per dose.